InSilico seeks IPO boost to get AI drugs over the line
The drug developer has raised around $400 million in seven rounds of financing. But after burning through cash, the company needs fresh capital to sustain its work on AI-assisted drugs…
Is Fosun Set to Rise Again as China Reopens?
The debt-heavy conglomerate announced a fresh $1 billion in asset sales last week, as growing signs emerge that its looming debt crisis of 2022 may be recedingKey Takeaways:Fosun International announced…
Fosun Pharma Sells Down BioNTech Stake, Though Divorce Looks Unlikely
The Chinese company profited handsomely from its investment in the German vaccine maker, and is most likely selling the stake to help service its parent’s large debtKey Takeaways:Fosun Pharma said…
FAST NEWS: Fosun Pharma’s Revenue Growth Slows Sharply in Third Quarter
The latest: Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH) said Sunday its revenue increased 1.7% year-on-year to 10.27 billion yuan ($1.4 billion) in the third quarter, as measured using…
FAST NEWS: Fosun Pharma Spends $160 Million on Singapore Cancer Clinic
The latest: Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH) announced Monday evening it will acquire a 60% stake in Oncocare Medical Pte Ltd, one of the local largest private medical…
Recent Articles
RELATED ARTICLES
-
HBM gets health boost from drug licensing deals
2142.HK -
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Everest reaches new heights on growing drug sales
1952.HK
-
AI drugs researcher QuantumPharm makes market debut on long road to profit
2228.HK
